Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Delayed Effects of Treatment in Cancer Survivors (DETECS)
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Status: Enrolling
Updated:  4/3/2017
University of Colorado Clinical and Translational Research Center
mi
from
Aurora, CO
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Status: Enrolling
Updated: 4/3/2017
University of Colorado Clinical and Translational Research Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Stanford University
mi
from
Stanford, CA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
University of Chicago
mi
from
Chicago, IL
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Johns Hopkins University
mi
from
Baltimore, MD
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Providence Oncology & Hematology Care Eastside
mi
from
Portland, OR
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Providence Oncology & Hematology Care Eastside
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated:  4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy
Status: Enrolling
Updated: 4/3/2017
Pathway Genomics
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
City of Hope National Medical Center
mi
from
Duarte, CA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology
mi
from
Los Angeles, CA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Sarcoma Oncology Center
mi
from
Santa Monica, CA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Kootenai Medical Center
mi
from
Coeur d'Alene, ID
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Kootenai Medical Center
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
NIH/NCI
mi
from
Bethesda, MD
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
NIH/NCI
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Massachusetts General Hospital; Dana Farber Partnes Cancer Center
mi
from
Boston, MA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Massachusetts General Hospital; Dana Farber Partnes Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Dana Farber Partners Can Ctr
mi
from
Boston, MA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Dana Farber Partners Can Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Nebraska Methodist Hospital; Onc Hem West
mi
from
Omaha, NE
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Nebraska Methodist Hospital; Onc Hem West
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Albert Einstein College of Medical Pediatrics; Department of Pediatrics
mi
from
Bronx, NY
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Albert Einstein College of Medical Pediatrics; Department of Pediatrics
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy
mi
from
Charlotte, NC
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Oregon Health & Science University Cancer Institute
mi
from
Portland, OR
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Oregon Health & Science University Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Pennsylvania Oncology Hema Asc
mi
from
Philadelphia, PA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Pennsylvania Oncology Hema Asc
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Texas Children's Cancer Center/Baylor College of Medicine
mi
from
Houston, TX
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Texas Children's Cancer Center/Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Huntsman Cancer Institute; Orthopedic Center
mi
from
Salt Lake City, UT
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Huntsman Cancer Institute; Orthopedic Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated:  4/3/2017
Peter Maccallum Cancer Institute; Medical Oncology
mi
from
Melbourne,
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Status: Enrolling
Updated: 4/3/2017
Peter Maccallum Cancer Institute; Medical Oncology
mi
from
Melbourne,
Click here to add this to my saved trials
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated:  4/3/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated: 4/3/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated:  4/3/2017
Washington University, St. Louis
mi
from
St. Louis, MO
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated: 4/3/2017
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated:  4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors
Status: Enrolling
Updated: 4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
St. Joseph's Hospital - Resurgeons Orthopedics
mi
from
Atlanta, GA
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
St. Joseph's Hospital - Resurgeons Orthopedics
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Arthritis & Joint Center - U. Mass. Memorial
mi
from
Worcester, MA
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Arthritis & Joint Center - U. Mass. Memorial
mi
from
Worcester, MA
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
PRESSD
mi
from
Southfield, MI
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
PRESSD
mi
from
Southfield, MI
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Montana Neuroscience Institute Foundation
mi
from
Missoula, MT
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Montana Neuroscience Institute Foundation
mi
from
Missoula, MT
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Syracuse Orthopedic Specialists
mi
from
Syracuse, NY
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Syracuse Orthopedic Specialists
mi
from
Syracuse, NY
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Neurosurgical Associates
mi
from
Nashville, TN
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Neurosurgical Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Brain & Spine of Texas
mi
from
Plano, TX
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Brain & Spine of Texas
mi
from
Plano, TX
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
UCSF
mi
from
San Francisco, CA
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Carrollton Orthopedics
mi
from
Carrollton, GA
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Carrollton Orthopedics
mi
from
Carrollton, GA
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Bluegrass Orthopedics & Hand Care Research
mi
from
Lexington, KY
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Bluegrass Orthopedics & Hand Care Research
mi
from
Lexington, KY
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Henry Ford West Bloomfield Hospital
mi
from
West Bloomfield, MI
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Henry Ford West Bloomfield Hospital
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Physicians Research Options Spine Center
mi
from
Las Vegas, NV
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Physicians Research Options Spine Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated:  4/4/2017
Buda Health Center
mi
from
Budapest,
Bone Graft Materials Observational Registry
A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice
Status: Enrolling
Updated: 4/4/2017
Buda Health Center
mi
from
Budapest,
Click here to add this to my saved trials
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/4/2017
Syracuse VA Medical Center
mi
from
Syracuse, NY
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/4/2017
Syracuse VA Medical Center
mi
from
Syracuse, NY
Click here to add this to my saved trials